|
KMID : 0368119920220020307
|
|
Korean Circulation Journal
1992 Volume.22 No. 2 p.307 ~ p.313
|
|
|
A Clinical Trial of Pravastatin in Korean patients with Hypercholesterolemia
|
|
박주형
안영근/정명호/조정관/박종춘/최기철/강정채
|
|
|
Abstract
|
|
|
Hypercholesterolemia is one of the major risk factors for atherosclerosis. Reduction of serum total and low density lipoprotein cholesterol (LDL-C) and the increase of high density lipoprotiein cholesterol (HDI-C) are known to be associated with
significant decrease of the incidence of atherosclerotic disease. HMG CoA reductase is nwon as rate limiting enzyme in the synthesis of cholesterol. Among many inhibitors of this enzyme pravastatin was recently relesed. To evaluate the efficacy
and
safety of this drug in Korean patients with hypercholesterolemia daily 5~40mg of pravstatin was admininstered in 30 patients after 4 weeks wash-out and followed in 4 week intervals up to 12 weeks.
1) Total cholesterol (TC) was decreased from 247.3±24.7mg/dl to 216.6±34.8mg/dl after 4 weeks. 214.3±36.7mg/dl after 8 weeks and 212.5±36.1mg/dl after 12 weeks (p<0.001. respectively).
2) Triglyceride (TG) was decreased from 191.3±77.9mg/dl to 161.4±61.4mg/dl after 4 weeks (p,0.05). 155.4±74.8mg/dl after 8 weeks (p<0.05) but after 12 weeks the level of triglyceride was 166.5±70.3mg/dl not significantly differenct from the
basal
leval.
3) LDL-C was decreased from 155.0±29.3mg/dl to 129.8±34.4mg/dl after 4 weeks. 132.0±32.4mg/dl after 8 weeks and 125.9±38.1mg/dl after 12 weeks (p<0.01. respectively).
4) HDL-C was not significantly changed during the trial.
5) TC/HDI-C ratio was decreased from 4.8±1.3 to 4.1±0.9 after 4 weeks, 4.3±0.9 after 8 weeks and 4.1±1.1 after 12 weeks (p<0.01. respectively).
6) LDL-C/HDL-C ratio was decreased from 3.0±1.0 to 2.5±0.8 after 4 weeks (p<0.01). 2.6±0.7 after 8 weeks (p<0.05) and 2.4±0.9 after 12 weeks (p<0.01).
7) The side effects of pravastatin were mild and transient. including I case of nausea. I headache. I flushing sensation on the face and 2 dizziness.
8) The laboratory studies including serum transanminases, uric acid, creatinine, creatine phosphokinase and blood glucose were not changed significantly.
These results suggested that pravastatin is an effective and relatively safe hypolipidemic agent in Korean adult patients with hypercholesterolemia.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|